✦ LIBER ✦

Antinuclear antibodies and glutamic acid decarboxylase antibodies in children with refractory epilepsy

✍ Scribed by Abd El-Aziz, Sahar A.; El-Serogy, Hesham

Book ID: 123248535
Publisher: Springer (Biomed Central Ltd.)
Year: 2013
Tongue: English
Weight: 487 KB
Volume: 61
Category: Article
ISSN: 1110-6638
DOI: 10.1016/j.epag.2013.05.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anticardiolipin, glutamic acid decarboxy

Anticardiolipin, glutamic acid decarboxylase, and antinuclear antibodies in epileptic patients

✍ A. Verrotti; R. Greco; E. Altobelli; G. Latini; G. Morgese; F. Chiarelli 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 47 KB

Epilepsy associated with glutamic acid d

Epilepsy associated with glutamic acid decarboxylase antibody (GADA)

✍ S. Liimatainen; J. Peltola 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB

Clinical significance of glutamic acid d

Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy

✍ Suvi Liimatainen; Maria Peltola; Lidia Sabater; Mahdi Fallah; Elham Kharazmi; An 📂 Article 📅 2009 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 179 KB

Epilepsy and cerebellar ataxia associate

Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies

✍ Vulliemoz, S; Vanini, G; Truffert, A; Chizzolini, C; Seeck, M 📂 Article 📅 2007 🏛 BMJ Publishing Group 🌐 English ⚖ 410 KB

Absence of glutamic acid decarboxylase a

Absence of glutamic acid decarboxylase antibodies in childhood epilepsies

✍ Heikki Rantala; Petri Kulmala; Kaisa Savola; Mikael Knip 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Glutamic acid decarboxylase antibodies i

Glutamic acid decarboxylase antibodies in idiopathic generalized epilepsy and type 1 diabetes

✍ Pasquale Striano; Giuseppe Perruolo; Luca Errichiello; Pietro Formisano; Frances 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 49 KB

colleagues' concern that there may be bias toward patients with more progressive disease in the control group compared with the treated group appears unlikely. The 20% of patients in the control group who had discontinued immunomodulatory or immunosuppressive treatment in the first 3 to 6 weeks bec